ABS-201 in Androgenetic Alopecia

Trial
100%50%0%Jun 25Jun 26Jun 27Jun 28Jun 29Jun 30Jul 1Jul 2Jul 3Jul 4Jul 5Jul 6Jul 7Jul 8Jul 9Jul 10Jul 11Jul 12Jul 13Jul 14Jul 15Jul 16Jul 17Jun 25 • YES 31.9%Jun 29 • YES 32.9%Jun 30 • YES 32.9%Jul 1 • YES 100.0%Jul 2 • YES 48.4%Jul 3 • YES 93.5%Jul 4 • YES 93.5%Jul 5 • YES 93.5%Jul 6 • YES 94.4%Jul 7 • YES 2.7%Jul 8 • YES 99.8%Jul 9 • YES 6.8%Jul 10 • YES 100.0%Jul 17 • YES 99.9%
Stock ($ABSI)Daily close · through Jul 17
No stock close$11.99$9.85$7.71Jun 25Jun 26Jun 27Jun 28Jun 29Jun 30Jul 1Jul 2Jul 3Jul 4Jul 5Jul 6Jul 7Jul 8Jul 9Jul 10Jul 11Jul 12Jul 13Jul 14Jul 15Jul 16Jul 17Jul 8 • ABSI $11.10Jul 9 • ABSI $11.47Jul 10 • ABSI $10.60Jul 13 • ABSI $10.21Jul 14 • ABSI $10.23Jul 15 • ABSI $9.76Jul 16 • ABSI $8.23Jul 17 • ABSI $8.30

Will Absci report a numerical improvement in Target Area Hair Count (TAHC) for ABS-201 in AGA patients by Dec. 31, 2026?

Create account to trade
Scientific editorial illustration for Androgenetic Alopecia

Androgenetic Alopecia

Androgenetic alopecia is common inherited hair thinning, called male or female pattern hair loss. Target area hair count matters because more hairs in a small scalp spot can mean fuller-looking coverage.

1U.S. Burden: 50M men; 30M women2Men By Age 50: 30% to 50%3Lifetime Prevalence: Up to 80% men; 50% women